Entrada Therapeutics, Inc. (TRDA) Tops Q3 EPS by 38c

Entrada Therapeutics, Inc. (NASDAQ: TRDA) reported Q3 EPS of ($0.35), $0.38 better than the analyst estimate of ($0.73). Revenue for the quarter came in at $19.57 million versus the consensus estimate of $12.32 million.

For earnings history and earnings-related data on Entrada Therapeutics, Inc. (TRDA) click here.

You May Also Be Interested In

• Citi upgrades Bath & Body Works to Buy with $25 price target
• uCloudlink Group Inc. (UCL) Misses Q2 EPS by 1c ; Offers Guidance
• Baidu (BIDU) Misses Q2 EPS by 262c, misses on revenue